Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.73 |
| ▸ | DRD2 | P14416 | 9/20 | 0.73 |
| ▸ | DRD3 | P35462 | 6/20 | 0.53 |
| ▸ | DRD4 | P21917 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933613 | 0.74 | KCNH2 (0.61) | GRM2DRD2DRD3DRD4RAB9A | |
| SCHEMBL4725109 | 0.73 | GRM2 (0.77) | GRM2DRD2DRD3DRD4MEN1 | |
| SCHEMBL4726289 | 0.72 | GRM2 (0.72) | GRM2DRD2DRD3DRD4MEN1 | |
| SCHEMBL4925251 | 0.72 | GRM2 (0.71) | GRM2DRD2DRD3DRD4MEN1 | |
| SCHEMBL4725327 | 0.71 | GRM2 (0.73) | GRM2DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL4777820 | 0.70 | GRM2 (0.72) | GRM2DRD2DRD3DRD4 | |
| SCHEMBL4728467 | 0.70 | DRD2 (0.72) | GRM2DRD2DRD3DRD4MEN1 | |
| SCHEMBL746995 | 0.68 | HCRTR1 (0.53) | GRM2DRD2RAB9AMEN1KMT2A | |
| SCHEMBL4152680 | 0.67 | GRM2 (0.71) | GRM2DRD2DRD4LMNAMAPT | |
| SCHEMBL5290305 | 0.66 | HTR2C (0.62) | DRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | GRM2 4477/4885DRD2 2308/4885DRD3 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.